A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Cencic R, Im YK, Naineni SK, Moustafa-Kamal M, Jovanovic P, Sabourin V, Annis MG, Robert F, Schmeing TM, Koromilas A, Paquet M, Teodoro JG, Huang S, Siegel PM, Topisirovic I, Ursini-Siegel J, Pelletier J.
Cencic R, et al. Among authors: robert f.
Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2318093121. doi: 10.1073/pnas.2318093121. Epub 2024 Jan 17.
Proc Natl Acad Sci U S A. 2024.
PMID: 38232291
Free PMC article.